The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S. Albert, Steven T. DeKosky, Dennis W Dickson, Bruno Dubois, Howard H. Feldman, Nick C. Fox, Anthony Gamst, David M. Holtzman, William J. Jagust, Ronald Carl Petersen, Peter J. Snyder, Maria C. Carrillo, Bill Thies, Creighton H. Phelps

Research output: Contribution to journalArticle

3903 Citations (Scopus)

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

Original languageEnglish (US)
Pages (from-to)270-279
Number of pages10
JournalAlzheimer's and Dementia
Volume7
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

National Institute on Aging (U.S.)
Alzheimer Disease
Biomarkers
Guidelines
Cerebrospinal Fluid
Research
Health Personnel
Clinical Trials
Cognitive Dysfunction

Keywords

  • AD dementia
  • Diagnosis
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. / Albert, Marilyn S.; DeKosky, Steven T.; Dickson, Dennis W; Dubois, Bruno; Feldman, Howard H.; Fox, Nick C.; Gamst, Anthony; Holtzman, David M.; Jagust, William J.; Petersen, Ronald Carl; Snyder, Peter J.; Carrillo, Maria C.; Thies, Bill; Phelps, Creighton H.

In: Alzheimer's and Dementia, Vol. 7, No. 3, 05.2011, p. 270-279.

Research output: Contribution to journalArticle

Albert, Marilyn S. ; DeKosky, Steven T. ; Dickson, Dennis W ; Dubois, Bruno ; Feldman, Howard H. ; Fox, Nick C. ; Gamst, Anthony ; Holtzman, David M. ; Jagust, William J. ; Petersen, Ronald Carl ; Snyder, Peter J. ; Carrillo, Maria C. ; Thies, Bill ; Phelps, Creighton H. / The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. In: Alzheimer's and Dementia. 2011 ; Vol. 7, No. 3. pp. 270-279.
@article{b543e0506def432db1d83a1ac33a85b8,
title = "The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease",
abstract = "The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.",
keywords = "AD dementia, Diagnosis, Mild cognitive impairment",
author = "Albert, {Marilyn S.} and DeKosky, {Steven T.} and Dickson, {Dennis W} and Bruno Dubois and Feldman, {Howard H.} and Fox, {Nick C.} and Anthony Gamst and Holtzman, {David M.} and Jagust, {William J.} and Petersen, {Ronald Carl} and Snyder, {Peter J.} and Carrillo, {Maria C.} and Bill Thies and Phelps, {Creighton H.}",
year = "2011",
month = "5",
doi = "10.1016/j.jalz.2011.03.008",
language = "English (US)",
volume = "7",
pages = "270--279",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The diagnosis of mild cognitive impairment due to Alzheimer's disease

T2 - Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

AU - Albert, Marilyn S.

AU - DeKosky, Steven T.

AU - Dickson, Dennis W

AU - Dubois, Bruno

AU - Feldman, Howard H.

AU - Fox, Nick C.

AU - Gamst, Anthony

AU - Holtzman, David M.

AU - Jagust, William J.

AU - Petersen, Ronald Carl

AU - Snyder, Peter J.

AU - Carrillo, Maria C.

AU - Thies, Bill

AU - Phelps, Creighton H.

PY - 2011/5

Y1 - 2011/5

N2 - The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

AB - The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

KW - AD dementia

KW - Diagnosis

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=79956084514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956084514&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.03.008

DO - 10.1016/j.jalz.2011.03.008

M3 - Article

C2 - 21514249

AN - SCOPUS:79956084514

VL - 7

SP - 270

EP - 279

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -